Sorrento Therapeutics, Inc. (SRNE) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sorrento Therapeutics, Inc. (SRNE) trades at $0.0008 with AI Score 53/100 (Grade B). Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for various diseases, including cancer and autoimmune disorders. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for SRNE: SRNE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SRNE against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SRNE: 1/3 scored disciplines lean bearish. Dominant signal: R&D Intensity strong.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sorrento Therapeutics, Inc. (SRNE) Healthcare & Pipeline Overview
Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted therapies for cancer and other serious diseases, utilizing its proprietary G-MAB antibody library and advanced drug delivery technologies to address unmet medical needs.
What Is the Investment Thesis for SRNE?
Sorrento Therapeutics, Inc. is positioned for growth through its diverse pipeline of innovative therapies targeting significant medical needs. Key value drivers include the ongoing development of anti-CD38 CAR-T therapy, which addresses a substantial market in multiple myeloma, and the Phase III trials for SEMDEXA, potentially tapping into the growing market for pain management solutions. The company's unique drug delivery technology, Sofusa, presents a competitive advantage in enhancing drug efficacy, particularly in oncology. With a gross margin of 46.8%, Sorrento's financial metrics indicate operational efficiency, although the company currently operates at a profit margin of -911.6%. As the biopharmaceutical industry continues to expand, driven by increasing demand for novel therapies, Sorrento's strategic collaborations and innovative product offerings position it favorably for future growth. Investors should monitor the progress of clinical trials and regulatory approvals as potential catalysts for stock performance.
Based on FMP financials and quantitative analysis
SRNE Key Highlights
Market Cap: $0.00B, indicating a current lack of market valuation due to trading on OTC markets.
- Profit Margin: -911.6%, reflecting significant operational challenges during clinical development phases.
- Gross Margin: 46.8%, demonstrating the potential for profitability upon successful product commercialization.
- Beta: 0.31, indicating lower volatility compared to the broader market, suggesting stability in investor sentiment.
- No Dividend Yield, as the company reinvests earnings into research and development.
Who Are SRNE's Competitors?
SRNE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SRNE's Key Strengths?
Innovative proprietary technologies like G-MAB and Sofusa.
- Diverse pipeline targeting multiple therapeutic areas.
- Strong collaborations with leading research institutions.
What Are SRNE's Weaknesses?
High operational costs leading to negative profit margins.
- Dependence on successful clinical trial outcomes for revenue generation.
- Limited market capitalization due to OTC trading.
What Could Drive SRNE Stock Higher?
Completion of Phase III trials for SEMDEXA, potentially leading to regulatory submission.
- Development of anti-CD38 CAR-T therapy with clinical trials progressing.
- Collaborations with SmartPharm Therapeutics and other institutions for COVID-19 therapeutics.
What Are the Key Risks for SRNE?
Financial-distress signal — its Altman Z-Score of -10.88 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges in obtaining approvals for new therapies.
- High operational costs leading to negative profit margins.
- Intense competition from established biotechnology companies.
What Are the Growth Opportunities for SRNE?
- With ongoing clinical trials, successful outcomes could lead to commercialization and significant revenue generation, enhancing Sorrento's market presence.
- Growth opportunity 2: The development of SEMDEXA, currently in Phase III trials for sciatica, targets the growing pain management market, expected to reach $90 billion by 2026. If approved, SEMDEXA could provide a non-opioid solution, tapping into the increasing demand for alternative pain therapies.
- Growth opportunity 3: Sorrento's collaboration with SmartPharm Therapeutics to develop a gene-encoded antibody vaccine for COVID-19 could lead to significant advancements in vaccine technology. Given the ongoing need for effective vaccines, this partnership may enhance Sorrento's reputation and market share in infectious disease therapeutics.
- Growth opportunity 4: The innovative Sofusa drug delivery technology presents an opportunity to revolutionize how biologics are administered, particularly in oncology. This technology could capture a share of the $50 billion oncology drug delivery market, enhancing treatment efficacy and patient outcomes.
- Growth opportunity 5: Sorrento's pipeline includes SP-103 and SP-104, targeting chronic low back pain and fibromyalgia, respectively. With chronic pain conditions affecting millions, these products could penetrate a market valued at over $80 billion, driving future growth and revenue.
What Threats Does SRNE Face?
- Intense competition from established biotechnology firms.
- Regulatory hurdles in obtaining approvals for new therapies.
- Market volatility affecting investor confidence in OTC stocks.
What Are SRNE's Competitive Advantages?
- Proprietary G-MAB antibody library providing a competitive edge in antibody development.
- Innovative drug delivery technologies like Sofusa enhancing treatment efficacy.
- Strong pipeline of diverse therapeutic candidates addressing significant medical needs.
- Strategic collaborations with reputable institutions enhancing research capabilities.
- Experienced management team with a proven track record in biotechnology.
What Does SRNE Do?
Founded in 2006 and headquartered in San Diego, California, Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharmaceutical company dedicated to developing innovative therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. The company operates through two segments: Sorrento Therapeutics and Scilex. Sorrento Therapeutics leverages its proprietary G-MAB antibody library to develop cancer therapeutics, employing advanced modalities such as chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody-drug conjugates. Additionally, the company has developed Sofusa, a unique drug delivery technology that enables biologics to be delivered directly into the lymphatic system, enhancing therapeutic efficacy. Sorrento's clinical pipeline includes several promising programs, such as anti-CD38 CAR-T therapy for multiple myeloma and resiniferatoxin, a non-opioid neurotoxin for late-stage cancer and osteoarthritis pain. The company also focuses on innovative treatments like ZTlido for postherpetic neuralgia and SEMDEXA, an injectable gel formulation for sciatica, currently in Phase III trials. Sorrento has established collaborations with notable institutions, including SmartPharm Therapeutics for COVID-19 vaccine development and Mayo Clinic for innovative drug delivery studies. With a dedicated workforce of 949 employees, Sorrento is positioned to make significant contributions to the biopharmaceutical landscape.
What Products and Services Does SRNE Offer?
- Develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases.
- Utilizes a proprietary G-MAB antibody library for targeted cancer therapeutics.
- Implements advanced drug delivery technologies, including CAR-T and antibody-drug conjugates.
- Conducts clinical trials for innovative treatments like resiniferatoxin and SEMDEXA.
- Collaborates with leading institutions for research and development of new therapies.
- Focuses on addressing unmet medical needs in various therapeutic areas.
How Does SRNE Make Money?
- Generates revenue through the development and commercialization of biopharmaceutical products.
- Engages in partnerships and collaborations to enhance research capabilities and market reach.
- Invests in clinical trials to advance product candidates toward regulatory approval.
- Explores licensing agreements for proprietary technologies and therapies.
- Utilizes a diverse pipeline to mitigate risks associated with individual product performance.
What Industry Does SRNE Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in genomics, personalized medicine, and innovative drug delivery systems. Sorrento Therapeutics operates in a competitive landscape, facing peers such as Amgen and Gilead Sciences, but differentiates itself through its proprietary technologies and diverse therapeutic pipeline. The industry's focus on precision medicine and novel therapies positions Sorrento to capitalize on emerging trends and market needs.
Who Are SRNE's Key Customers?
- Healthcare providers seeking innovative treatment options for patients.
- Pharmaceutical companies interested in collaborations and licensing agreements.
- Research institutions involved in clinical trials and therapeutic development.
- Patients suffering from chronic and serious medical conditions.
- Investors looking for opportunities in the biotechnology sector.
Company Profile
Sorrento Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Henry H. Ji. SRNE has traded publicly since 2007.
How Sorrento Therapeutics, Inc. Is Valued
Relative to its peer group, SRNE's quantitative score of 53/100 is below the peer average of 79/100.
Financial Health
Sorrento Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.88 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Sorrento Therapeutics, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 33.9% below estimates on average.
Forward Outlook
Wall Street analysts project Sorrento Therapeutics, Inc. revenue of about $591.4M for fiscal 2026, with EPS near $0.44.
Insider Activity
The most recent 12 insider filings for Sorrento Therapeutics, Inc. break down as 3 sales and 9 purchases. On net that is roughly 4.2M shares acquired (about $317K) — insiders putting money in tends to read as conviction.
SRNE Financials
Bull Case vs Bear Case
Bull Case
- Sorrento's recent focus on strategic partnerships suggests potential revenue streams and market expansion. Think of it like Novavax in 2020, betting on partnerships to validate their tech.
- The community's enthusiasm around Sorrento's pipeline progress could drive positive market perception. It's similar to how initial positive sentiment fueled Moderna's early gains.
- Insider buying activity, if any, often signals confidence in the company's future prospects. It's a vote of confidence, like when Elon Musk buys Tesla shares.
- Positive community sentiment may reflect belief in Sorrento's long-term vision and innovation. This can create a self-fulfilling prophecy, like the early days of Amazon.
Bear Case
- Recent mixed community sentiment may indicate uncertainty about the company's ability to execute its plans. It echoes concerns around Peloton's growth after the initial pandemic boom.
- Potential regulatory hurdles for Sorrento's drug candidates might delay market entry. This is similar to Biogen's Aduhelm controversy and its impact on market confidence.
- Negative community sentiment around competition in the biotech space could pressure the stock. Think of generic drug competition eroding Pfizer's market share.
- Any lack of consistent positive news flow might dampen investor enthusiasm and create selling pressure. This is akin to the market losing interest in GoPro after initial hype faded.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SRNE Latest News
No recent news available for SRNE.
SRNE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SRNE.
Price Targets
Wall Street price target analysis for SRNE.
SRNE MoonshotScore
What does this score mean?
The MoonshotScore rates SRNE 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Henry H. Ji
CEO
Henry H. Ji has extensive experience in the biotechnology sector, having co-founded Sorrento Therapeutics in 2006. He holds a Ph.D. in Molecular Biology from the University of California, San Diego, and has held various leadership roles in biopharmaceutical companies, focusing on drug development and commercialization.
Track Record: Under Henry H. Ji's leadership, Sorrento has advanced its therapeutic pipeline significantly, securing collaborations with major research institutions and achieving milestones in clinical development. His strategic vision has positioned the company for future growth in the competitive biotechnology landscape.
SRNE OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers like OTCQX or OTCQB, often resulting in less stringent reporting standards. This tier is typically associated with lower liquidity and transparency compared to NYSE or NASDAQ listings.
- OTC Tier: OTC Other
- Limited financial disclosure compared to companies listed on major exchanges.
- Potential for higher volatility and lower liquidity in trading.
- Regulatory risks associated with the biopharmaceutical industry.
- Verify the company's clinical trial progress and results.
- Review financial statements and funding sources.
- Assess the management team's track record and experience.
- Investigate partnerships and collaborations for strategic value.
- Monitor industry trends and competitive landscape.
- Established collaborations with reputable institutions like Mayo Clinic.
- Presence of proprietary technologies with potential market applications.
- A dedicated workforce focused on innovative therapeutic development.
Common Questions About SRNE (Healthcare)
What does the AI Score mean for SRNE?
SRNE holds an AI Score of 53/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for various diseases, including cancer and autoimmune disorders. Founded …
What does Sorrento Therapeutics, Inc. do?
Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. The company utilizes its proprietary G-MAB antibody library and advanced drug delivery technologies to create targeted therapeutics, with a diverse pipeline addressing significant medical needs.
What are the main risks for SRNE?
Sorrento Therapeutics faces several risks, including regulatory hurdles that could delay or prevent the approval of its therapies, high operational costs that contribute to negative profit margins, and intense competition from established biotechnology firms. Additionally, the company's reliance on successful clinical trials for revenue generation poses inherent risks associated with drug development.
What growth opportunities does Sorrento Therapeutics, Inc. have in healthcare?
The company is also advancing SEMDEXA for sciatica, tapping into the $90 billion pain management market, and leveraging its innovative Sofusa drug delivery technology to enhance treatment efficacy in oncology.
What are the key factors to evaluate for SRNE?
Sorrento Therapeutics, Inc. (SRNE) holds an AI score of 53/100 (moderate). is positioned for growth through its diverse pipeline of innovative therapies targeting significant medical needs. Not financial advice.
How frequently does SRNE data refresh on this page?
SRNE's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SRNE's recent stock price performance?
Sorrento Therapeutics, Inc. (SRNE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative proprietary technologies like G-MAB and Sofusa. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SRNE overvalued or undervalued right now?
Sorrento Therapeutics, Inc. (SRNE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SRNE before investing?
Before investing in Sorrento Therapeutics, Inc. (SRNE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the latest available reports.
- Some risks and opportunities are subject to change based on market conditions.